Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia

International Urology and Nephrology

Volumn 52, Issue 6, 2020, Pages 999-1008

  Tanneru, Karthik ^a   Gautam, Shiva ^a   Norez, Daniel ^a   Kumar, Jatinder ^a   Alam, Muhammad Umar ^a   Koocheckpour, Shahriar ^a   Balaji, K C ^a   Joseph, Costa ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

BPH; LUTS; Prostatic urethral lift; PUL; Urolift

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; FLOW RATE; FUNCTIONAL STATUS; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATIC URETHRAL LIFT; QUALITY OF LIFE; REVIEW; SEXUAL HEALTH; SYSTEMATIC REVIEW; FOLLOW UP; MALE; MALE GENITAL SYSTEM SURGERY; PROCEDURES; TIME FACTOR; URETHRA;

FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC HYPERPLASIA; TIME FACTORS; URETHRA; UROLOGIC SURGICAL PROCEDURES, MALE;

EID: 85079866970     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-020-02408-y     Document Type: Review

References (35)

1. St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ (2006) Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 175(3 Pt 1):1018–1022. 10.1016/s0022-5347(05)00408-8 (discussion 980) DOI: 10.1016/s0022-5347(05)00408-8
2. Ally M, Lee T, Ecclestone H, Teo L, Kavia R (2017) Malignant features of a benign waiting list. J Clin Urol 10(2):105–109 DOI: 10.1177/2051415816671041
3. Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin 95(1):87–100
4. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44(5):539–545. 10.1016/s0302-2838(03)00376-2 DOI: 10.1016/s0302-2838(03)00376-2
5. Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50(5):969–979. 10.1016/j.eururo.2005.12.042 (discussion 980) DOI: 10.1016/j.eururo.2005.12.042
6. Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, Stief CG, Woo HH, Gratzke C (2017) Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol 72(6):986–997. 10.1016/j.eururo.2017.07.005 DOI: 10.1016/j.eururo.2017.07.005
7. Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, Somani BK (2016) Medium-term outcomes of urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 97:20–24. 10.1016/j.urology.2016.05.003 DOI: 10.1016/j.urology.2016.05.003
8. Magistro G, Stief CG, Woo HH (2018) Mini-review: what is new in urolift? Eur Urol Focus 4(1):36–39. 10.1016/j.euf.2018.01.013 DOI: 10.1016/j.euf.2018.01.013
9. Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, Roehrborn CG (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88. 10.1111/j.1464-410X.2011.10342.x DOI: 10.1111/j.1464-410X.2011.10342.x
10. Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, Roehrborn CG, Woo HH (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11. 10.1016/j.urology.2011.10.021 DOI: 10.1016/j.urology.2011.10.021
11. McNicholas TA, Woo HH, Chin PT, Bolton D, Fernandez Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299. 10.1016/j.eururo.2013.01.008 DOI: 10.1016/j.eururo.2013.01.008
12. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P (2015) Three year results of the prostatic urethral LIFT study. Can J Urol 22(3):7772–7782
13. Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB (2017) Five year results of the prospective randomized controlled prostatic urethral LIFT study. Can J Urol 24(3):8802–8813
14. Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH (2014) Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615–622. 10.1111/bju.12540 DOI: 10.1111/bju.12540
15. Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643–652. 10.1016/j.eururo.2015.04.024 DOI: 10.1016/j.eururo.2015.04.024
16. Bozkurt A, Karabakan M, Keskin E, Hirik E, Balci MB, Nuhoglu B (2016) Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Int 96(2):202–206. 10.1159/000441850 DOI: 10.1159/000441850
17. Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767–775. 10.1111/bju.13714 DOI: 10.1111/bju.13714
18. Rukstalis D, Rashid P, Bogache WK, Tutrone RF, Barkin J, Chin PT, Woo HH, Cantwell AL, Cowan BE, Bolton DM (2016) 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int 118(Suppl 3):14–22. 10.1111/bju.13666 DOI: 10.1111/bju.13666
19. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P (2018) Prostatic urethral lift: does size matter? J Endourol 32(7):635–638. 10.1089/end.2017.0855 DOI: 10.1089/end.2017.0855
20. Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, Miller F, Wetterauer U, Volkmer B, Gratzke C, Amend B (2019) Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 37(7):1353–1360. 10.1007/s00345-018-2494-1 DOI: 10.1007/s00345-018-2494-1
21. Garcia C, Chin P, Rashid P, Woo HH (2015) Prostatic urethral lift: a minimally invasive treatment for benign prostatic hyperplasia. Prostate Int 3(1):1–5. 10.1016/j.prnil.2015.02.002 DOI: 10.1016/j.prnil.2015.02.002
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. 10.1371/journal.pmed.1000100 DOI: 10.1371/journal.pmed.1000100
23. Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta‐analyses. Cochrane Handb Syst Rev Interv, pp 241–284
24. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557. 10.1016/s0022-5347(17)36966-5 (discussion 1564) DOI: 10.1016/s0022-5347(17)36966-5
25. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD (2004) Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 64(4):777–782. 10.1016/j.urology.2004.04.056 DOI: 10.1016/j.urology.2004.04.056
26. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898 10.1136/bmj.l4898 DOI: 10.1136/bmj.l4898
27. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:4919 DOI: 10.1136/bmj.i4919
28. McGuinness LA (2019) Robvis: an R package and web application for visualising risk-of-bias assessments. https://github.com/mcguinlu/robvis
29. von Hippel PT (2015) The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol 15:35. 10.1186/s12874-015-0024-z DOI: 10.1186/s12874-015-0024-z
30. Strope SA, Vetter J, Elliott S, Andriole GL, Olsen MA (2015) Use of medical therapy and success of laser surgery and transurethral resection of the prostate for benign prostatic hyperplasia. Urology 86(6):1115–1122. 10.1016/j.urology.2015.07.019 DOI: 10.1016/j.urology.2015.07.019
31. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM (2006) Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 6:14. 10.1186/1471-2490-6-14 DOI: 10.1186/1471-2490-6-14
32. Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ (2012) Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 10.1002/14651858.CD004135.pub3 DOI: 10.1002/14651858.CD004135.pub3
33. Eure G, Gange S, Walter P, Khan A, Chabert C, Mueller T, Cozzi P, Patel M, Freedman S, Chin P, Ochs S, Hirsh A, Trotter M, Grier D (2019) Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol 33(7):576–584. 10.1089/end.2019.0167 DOI: 10.1089/end.2019.0167
34. Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P (2019) Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 5:Cd012832. 10.1002/14651858.CD012832.pub2 DOI: 10.1002/14651858.CD012832.pub2
35. US Department of Health and Human Services CfMaMSPBNSDF (2016) https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Part-B-National-Summary-Data-File/Overview.html.